RESUMEN
In this paper, we present novel well-defined unimolecular micelles constructed a on poly(furfuryl glycidyl ether) core and highly hydrophilic poly(glyceryl glycerol ether) shell, PFGE-b-PGGE. The copolymer was synthesized via anionic ring-opening polymerization of furfuryl glycidyl ether and (1,2-isopropylidene glyceryl) glycidyl ether, respectively. MTT assay revealed that the copolymer is non-cytotoxic against human cervical cancer endothelial (HeLa) cells. The copolymer thanks to furan moieties in its core is capable of encapsulation of nifuratel, a hydrophobic nitrofuran derivative, which is a drug applied in the gynaecology therapies that shows a broad antimicroorganism spectrum. The study shows high loading capacity of the copolymer, i.e., 146 mg of nifuratel per 1 g of copolymer. The load unimolecular micelles were characterized using DLS and TEM microscopy and compared with the reference glyceryl glycerol ether homopolymer sample. The presence of numerous 1,2-diol moieties in the shell of PFGE-b-PGG macromolecules enabled the formation of reversible cross-links with 2-acrylamidephenylboronic acid-based polyacrylamide. The obtained hydrogels were both injectable and self-healable, which was confirmed with a rheological study.
Asunto(s)
Antifúngicos/química , Antitricomonas/química , Compuestos Epoxi/química , Furanos/química , Glicerol/química , Hidrogeles/química , Nifuratel/química , Polímeros/química , Antifúngicos/administración & dosificación , Antitricomonas/administración & dosificación , Excipientes/química , Éteres de Glicerilo/química , Inyecciones , Nifuratel/administración & dosificación , SolubilidadRESUMEN
Microporous polymeric matrices prepared from poly(É-caprolactone) [PCL] were evaluated for controlled vaginal delivery of the antiprotozoal agent (tinidazole) in the treatment of the sexually transmitted infection, trichomoniasis. The matrices were produced by rapidly cooling co-solutions of PCL and tinidazole in acetone to -80 °C to induce crystallisation and hardening of the polymer. Tinidazole incorporation in the matrices increased from 1.4 to 3.9% (w/w), when the drug concentration in the starting PCL solution was raised from 10 to 20% (w/w), giving rise to drug loading efficiencies up to 20%. Rapid 'burst release' of 30% of the tinidazole content was recorded over 24 h when the PCL matrices were immersed in simulated vaginal fluid. Gradual drug release occurred over the next 6 days resulting in delivery of around 50% of the tinidazole load by day 7 with the released drug retaining antiprotozoal activity at levels almost 50% that of the 'non-formulated' drug in solution form. Basic modelling predicted that the concentration of tinidazole released into vaginal fluid in vivo from a PCL matrix in the form of an intravaginal ring would exceed the minimum inhibitory concentration against Trichomonas vaginalis. These findings recommend further investigation of PCL matrices as intravaginal devices for controlled delivery of antiprotozoal agents in the treatment and prevention of sexually transmitted infections.
Asunto(s)
Antitricomonas/administración & dosificación , Enfermedades de Transmisión Sexual/tratamiento farmacológico , Tinidazol/administración & dosificación , Tricomoniasis/tratamiento farmacológico , Administración Intravaginal , Antitricomonas/química , Antitricomonas/farmacología , Química Farmacéutica/métodos , Cristalización , Preparaciones de Acción Retardada , Sistemas de Liberación de Medicamentos , Liberación de Fármacos , Femenino , Humanos , Pruebas de Sensibilidad Parasitaria , Polímeros/química , Porosidad , Enfermedades de Transmisión Sexual/parasitología , Tinidazol/química , Tinidazol/farmacología , Vagina/parasitologíaRESUMEN
The 7-benzylidenenaltrexone (BNTX) derivatives 2a-v, 3a-c, 13a-c, and 14a were synthesized from naltrexone (1) and evaluated for their antitrichomonal activity. The structure-activity-relationship studies found that 4-iodo-BNTX (2g) showed the highest activity (IC50=10.5µM) and the affinity for the opioid receptor was less important for antitrichomonal activity against Trichomonas vaginalis. The morphinan skeleton bearing both the double bond for a Michael acceptor and the phenolic hydroxy group would be a specific template for development of antitrichomonal agents. In addition, the mechanism of the antitrichomonal activity of the BNTX derivatives may differ from that of the standard drug, metronidazole.
Asunto(s)
Antitricomonas/farmacología , Compuestos de Bencilideno/farmacología , Naltrexona/análogos & derivados , Receptores Opioides delta/antagonistas & inhibidores , Trichomonas vaginalis/efectos de los fármacos , Animales , Antitricomonas/síntesis química , Antitricomonas/química , Compuestos de Bencilideno/síntesis química , Compuestos de Bencilideno/química , Células CHO , Cricetulus , Relación Dosis-Respuesta a Droga , Estructura Molecular , Naltrexona/síntesis química , Naltrexona/química , Naltrexona/farmacología , Relación Estructura-ActividadRESUMEN
Tritrichomonas foetus infects the bovine urogenital tract, causing bovine trichomoniasis. Significant economic losses may occur due to infertility and abortion among cattle. Trichomonas vaginalis is the causative agent of trichomoniasis; the most common but overlooked non-viral sexually transmitted disease worldwide. Human and bovine trichomoniasis present treatment restrictions and efforts to identify new alternatives are essential. The present study evaluated the anti-trichomonads activities of seven fractions from northwest endemic plant Manilkara rufula. Flavonoids and condensed tannins were identified from these fractions by LC-DAD-MS/MS and MALDI-MS/MS. Altogether, the results demonstrated for the first time the structural description of tannins from leaves of M. rufula and the relation of these compounds with anti-T. vaginalis and anti-T. foetus activities. Overall, this report reveals the potential of M. rufula fractions against both parasites and shows new alternatives to treat the infection caused by trichomonads.
Asunto(s)
Antitricomonas/farmacología , Flavonoides/farmacología , Manilkara/química , Extractos Vegetales/farmacología , Taninos/farmacología , Trichomonas vaginalis/efectos de los fármacos , Tritrichomonas foetus/efectos de los fármacos , Antitricomonas/química , Antitricomonas/aislamiento & purificación , Brasil , Línea Celular , Supervivencia Celular , Cromatografía Liquida , Células Epiteliales/efectos de los fármacos , Flavonoides/química , Flavonoides/aislamiento & purificación , Células HeLa , Humanos , Estructura Molecular , Extractos Vegetales/química , Extractos Vegetales/aislamiento & purificación , Hojas de la Planta/química , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción , Taninos/química , Taninos/aislamiento & purificación , Trichomonas vaginalis/fisiología , Tritrichomonas foetus/fisiologíaRESUMEN
Bioisosteric ferrocenyl-containing quinolines and ferrocenylamines containing organosilanes and their carbon analogues, were prepared and fully characterised. The molecular structures of two ferrocenyl-containing quinolines, determined using single-crystal X-ray diffraction, revealed that the compounds crystallise in a folded conformation. The compounds were screened for their antiplasmodial activity against the chloroquine-sensitive (NF54) and CQ-resistant (Dd2) strains of P. falciparum, as well as for their cytotoxicity against Chinese Hamster Ovarian (CHO) cells. The ferrocenyl-containing quinolines displayed activities in the low nanomolar range (6-36 nM), and showed selectivity towards parasites. ß-Haematin inhibition assays suggest that the compounds may in part act via the inhibition of haemozoin formation, while microsomal metabolic stability studies reveal that the ferrocenyl-containing quinolines are rapidly metabolised in liver microsomes. Further, antitrichomonal screening against the metronidazole-sensitive (G3) strain of the mucosal pathogen T. vaginalis revealed that the quinoline-based compounds displayed superior parasite growth inhibition when compared to the ferrocenylamines. The library was also tested E. coli and on Lactobacilli spp. found as part of the normal flora of the human microbiome and no effect on growth in vitro was observed, supporting the observation that these compounds are specific for eukaryotic pathogens.
Asunto(s)
Antimaláricos/síntesis química , Antitricomonas/síntesis química , Compuestos Ferrosos/síntesis química , Quinolinas/síntesis química , Animales , Antimaláricos/química , Antimaláricos/farmacología , Antitricomonas/química , Antitricomonas/farmacología , Células CHO , Supervivencia Celular/efectos de los fármacos , Cricetulus , Diseño de Fármacos , Compuestos Ferrosos/química , Compuestos Ferrosos/farmacología , Plasmodium falciparum/efectos de los fármacos , Quinolinas/química , Quinolinas/farmacología , Trichomonas vaginalis/efectos de los fármacosRESUMEN
A selection of 1,2-disubstituted 5-nitroindazolin-3-ones (1-19) and 3-alkoxy-5-nitroindazoles substituted at positions 1 (20-24) or 2 (25-39) from our in-house compound library were screened in vitro against the most common curable sexually transmitted pathogen, Trichomonas vaginalis. A total of 41% of the studied molecules (16/39) achieved a significant activity of more than 85% growth inhibition at the highest concentration assayed (100 µg mL(-1)). Among these compounds, 3-alkoxy-5-nitroindazole derivatives 23, 24, 25 and 27 inhibited parasite growth by more than 50% at 10 µg mL(-1). In addition, the first two compounds (23, 24) still showed remarkable activity at the lowest dose tested (1 µg mL(-1)), inhibiting parasite growth by nearly 40%. Their specific activity towards the parasite was corroborated by the determination of their non-specific cytotoxicity against mammalian cells. The four mentioned compounds exhibited non-cytotoxic profiles at all of the concentrations assayed, showing a fair antiparasitic selectivity index (SI > 7·5). In silico studies were performed to predict pharmacokinetic properties, toxicity and drug-score using Molinspiration and OSIRIS computational tools. The current in vitro results supported by the virtual screening suggest 2-substituted and, especially, 1-substituted 3-alkoxy-5-nitroindazoles as promising starting scaffolds for further development of novel chemical compounds with the main aim of promoting highly selective trichomonacidal lead-like drugs with adequate pharmacokinetic and toxicological profiles.
Asunto(s)
Antitricomonas/farmacología , Indazoles/farmacología , Tricomoniasis/tratamiento farmacológico , Trichomonas vaginalis/efectos de los fármacos , Alcoholes/química , Animales , Antitricomonas/efectos adversos , Antitricomonas/química , Supervivencia Celular , Chlorocebus aethiops , Simulación por Computador , Indazoles/efectos adversos , Indazoles/química , Pruebas de Sensibilidad Parasitaria , Relación Estructura-Actividad , Células VeroRESUMEN
Nucleoside salvage pathway enzymes used by Trichomonas vaginalis are distinct from the pathway involved in activation of existing 5-nitroimidazole drugs. They thus represent excellent targets for developing novel, mechanism-based antitrichomonal agents. The purine-specific adenosine/guanosine preferring ribohydrolase (AGNH) was screened against the NIH Clinical Collection to assess its druggability. Eight compounds, including five flavonoids, were identified with IC50 values ⩽10 µM and confirmed in counter screens run in the presence of detergent. The inhibitors are structurally distinct from inhibitors of the pyrimidine-specific uridine ribohydrolase (UNH) thus indicating that AGNH is a distinct, druggable target from UNH.
Asunto(s)
Antitricomonas/química , Flavonoides/química , N-Glicosil Hidrolasas/antagonistas & inhibidores , Adenosina/análogos & derivados , Adenosina/química , Ensayos Analíticos de Alto Rendimiento , Quercetina/análogos & derivados , Quercetina/química , Bibliotecas de Moléculas Pequeñas/química , Estereoisomerismo , Trichomonas vaginalisRESUMEN
We evaluated antitrichomonal effects of δ opioid receptor (DOR) agonists and antagonists. Although all the agonists were inactive, the DOR antagonists BNTX (2a) and its derivatives 2b-d showed antitrichomonal activity with MIC of 20-40 µM. In addition, the development of a more effective synthetic method for the BNTX derivatives was achieved by using the Knoevenagel condensation.
Asunto(s)
Antitricomonas/química , Antitricomonas/farmacología , Compuestos de Bencilideno/farmacología , Naltrexona/análogos & derivados , Receptores Opioides delta/agonistas , Receptores Opioides delta/antagonistas & inhibidores , Vaginitis por Trichomonas/tratamiento farmacológico , Antitricomonas/síntesis química , Compuestos de Bencilideno/síntesis química , Compuestos de Bencilideno/química , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Estructura Molecular , Naltrexona/síntesis química , Naltrexona/química , Naltrexona/farmacología , Relación Estructura-ActividadRESUMEN
Two series of ten novel 7-nitroquinoxalin-2-ones and ten 6-nitroquinoxaline-2,3-diones with diverse substituents at positions 1 and 4 were synthesized and evaluated against the sexually transmitted parasite Trichomonas vaginalis. Furthermore, diverse molecular and drug-likeness properties were analyzed to predict the oral bioavailability following the Lipinski's "rule of five". 7-Nitroquinoxalin-2-one derivatives displayed moderate to high in vitro activity while the efficiency of most nitroquinoxaline-2,3-diones was rather low; both kinds of compounds did not show cytotoxic effects in mammalian cells. 7-Nitro-4-(3-piperidinopropyl)quinoxalin-2-one 9 achieved the highest trichomonacidal activity (IC50 = 18.26 µM) and was subsequently assayed in vivo in a murine model of trichomonosis. A 46.13% and a 50.70% reduction of pathogenic injuries were observed in the experimental groups treated orally during 7 days with 50 mg/kg and 100 mg/kg doses. The results obtained in the biological assays against T. vaginalis indicate that compounds with ω-(dialkylamino)alkyl substituents and a keto group at positions 4 and 2 of quinoxaline ring, respectively, provide interesting structural cores to develop novel prototypes to enhance the nitroquinoxalinones activity as trichomonacidal agents with interesting ADME properties according to virtual screening analysis.
Asunto(s)
Antitricomonas/síntesis química , Antitricomonas/farmacología , Quinoxalinas/farmacología , Tricomoniasis/tratamiento farmacológico , Trichomonas vaginalis/efectos de los fármacos , Animales , Antitricomonas/química , Células Cultivadas , Chlorocebus aethiops , Relación Dosis-Respuesta a Droga , Femenino , Ratones , Estructura Molecular , Pruebas de Sensibilidad Parasitaria , Quinoxalinas/síntesis química , Quinoxalinas/química , Relación Estructura-Actividad , Células VeroRESUMEN
Trinidad and Tobago is a twin-island Republic in the Caribbean and like many developing countries, it has included generic drugs on the national drug formulary to decrease the financial burden of pharmaceutical medications. However, to ensure that medications received by patients are beneficial, generic drugs need to be interchangeable with the innovator which has demonstrated safety, efficacy, and quality. The objective of the study was to compare the dissolution profiles and weight variations for different formulations of amoxicillin, metronidazole, and zidovudine that are on the national drug formulary and marketed in Trinidad and Tobago. All the products investigated are categorized as class 1 drugs according to the Biopharmaceutics Classification System (BCS) and the dissolution profiles were assessed according to the World Health Organization (WHO) criteria for interchangeability between products. The similarity factor, f 2, was used to determine sameness between the products. No generic formulation was found to be similar to Amoxil® 500-mg capsules. The two generic products for metronidazole 200-mg tablets demonstrated more than 85% drug release within 15 min in all three of the buffers; however, their 400-mg counterparts did not fulfill this requirement. The zidovudine 300-mg tablet complied with the requirements in buffer pH 4.5 and simulated gastric fluid (SGF) but not for simulated intestinal fluid (SIF). Some Class 1 pharmaceutical formulations may possess the same active ingredient and amount of drug but may show significant differences to in vitro equivalence requirements. Nevertheless, the dissolution process is suitable to detect these variations.
Asunto(s)
Amoxicilina/química , Amoxicilina/normas , Antibacterianos/química , Antibacterianos/normas , Fármacos Anti-VIH/química , Fármacos Anti-VIH/normas , Antitricomonas/química , Antitricomonas/normas , Liberación de Fármacos , Medicamentos Genéricos/química , Medicamentos Genéricos/normas , Metronidazol/química , Metronidazol/normas , Zidovudina/química , Zidovudina/normas , Cápsulas/análisis , Química Farmacéutica , Cromatografía Líquida de Alta Presión , Solubilidad , Comprimidos/análisis , Trinidad y TobagoRESUMEN
Biowaivers are recommended for immediate-release solid oral dosage forms using dissolution testing as a surrogate for in vivo bioequivalence studies. Several guidance are currently available (the World Health Organization (WHO), the US FDA, and the EMEA) where the conditions are described. In this study, definitions, criteria, and methodologies according to the WHO have been applied. The dissolution performances of immediate-release metronidazole, zidovudine, and amoxicillin products purchased in South African and Indian markets were compared to the relevant comparator pharmaceutical product (CPP)/reference product. The dissolution performances were studied using US Pharmacopeia (USP) apparatus 2 (paddle) set at 75 rpm in each of three dissolution media (pH1.2, 4.5, and 6.8). Concentrations of metronidazole, zidovudine, and amoxicillin in each dissolution media were determined by HPLC. Of the 11 metronidazole products tested, only 8 could be considered as very rapidly dissolving products as defined by the WHO, whereas 2 of those products could be considered as rapidly dissolving products but did not comply with the f 2 acceptance criteria in pH 6.8. All 11 zidovudine products were very rapidly dissolving, whereas in the case of the 14 amoxicillin products tested, none of those products met any of the WHO criteria. This study indicates that not all generic products containing the same biopharmaceutics classification system (BCS) I drug and in similar strength and dosage form are necessarily in vitro equivalent. Hence, there is a need for ongoing market surveillance to determine whether marketed generic products containing BCS I drugs meet the release requirements to confirm their in vitro bioequivalence to the respective reference product.
Asunto(s)
Amoxicilina/química , Antibacterianos/química , Fármacos Anti-VIH/química , Antitricomonas/química , Metronidazol/química , Zidovudina/química , Química Farmacéutica , Formas de Dosificación , Liberación de Fármacos , Medicamentos Genéricos , India , Solubilidad , SudáfricaRESUMEN
Trichomoniasis is the most prevalent, curable sexually transmitted disease (STD), which increases risk of viral STDs and HIV. However, drug resistance has been developed by some strains of Trichomonas vaginalis against Metronidazole (MTZ), the FDA approved drug against trichomoniasis. In the present study twenty two chalcone hybrids of metronidazole have been synthesized in a quest to get new molecules with higher potential against metronidazole-resistant T. vaginalis. All new hybrid molecules were found active against T. vaginalis with varying levels of activity against MTZ-susceptible and resistant strains. Eight compounds (4a, 4c, 4d, 4e, 4f, 4h, 4q and 4s) were found as active as the standard drug with an MIC of 1.56 µg/ml against MTZ-susceptible strain. However, compounds 4e, 4h and 4m were 4-times more active than MTZ against drug-resistant T. vaginalis, amongst which 4e and 4h were most promising against both susceptible and resistant strains.
Asunto(s)
Antitricomonas/farmacología , Chalcona/farmacología , Farmacorresistencia Bacteriana/efectos de los fármacos , Metronidazol/farmacología , Trichomonas vaginalis/efectos de los fármacos , Antitricomonas/síntesis química , Antitricomonas/química , Chalcona/química , Relación Dosis-Respuesta a Droga , Femenino , Células HeLa , Humanos , Metronidazol/química , Pruebas de Sensibilidad Microbiana , Estructura Molecular , Relación Estructura-Actividad , Vaginitis por Trichomonas/tratamiento farmacológicoRESUMEN
The compound VAM2-6 (1-methyl-7-nitro-4-(5-(piperidin-1-yl)pentyl)-3,4-dihydroquinoxalin-2(1H)-one) has previously been shown to have an in vitro efficacy of 100% at a concentration of 100 µg ml(-1) against Trichomonas vaginalis, a protozoon parasite that causes the sexually transmitted disease trichomoniasis. Because VAM2-6 is a quinoxaline derivative and given the lack of studies on the genotoxic activity of this compound, the present study was undertaken to evaluate its ability to induce DNA damage in the peripheral blood of mice using single-cell gel electrophoresis (SCGE or comet assay) and the micronucleus (MN) assay. Cell viability was assessed using a fluorochrome-mediated viability test. The compound was tested on CD1 mice at 60, 40 and 10 mg kg(-1) body weight administrated intraperitoneal (i.p.) in a single dose. Peripheral blood samples were collected 24 and 48 h after treatment. N-Ethyl-N-nitrosourea (ENU) was used as a positive control for the comet and micronucleus assays. The results showed that i.p. VAM2-6 induced single-strand DNA breaks and increased the average number of micronuclei in the treated mice in a dose-dependent manner at 60, 40 and 10 mg kg(-1). Cell viability decreased at 24 h but recovered at 48 h for all three evaluated doses. Therefore, the chemical structure of VAM2-6 should be modified to reduce its genotoxic potential.
Asunto(s)
Antitricomonas/toxicidad , Daño del ADN , Micronúcleos con Defecto Cromosómico/inducido químicamente , Piperidinas/toxicidad , Quinoxalinas/toxicidad , Animales , Antitricomonas/química , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Ensayo Cometa , Relación Dosis-Respuesta a Droga , Dosificación Letal Mediana , Masculino , Ratones , Ratones Endogámicos , Pruebas de Micronúcleos , Estructura Molecular , Piperidinas/química , Quinoxalinas/química , Pruebas de ToxicidadRESUMEN
Periodontitis is caused by periodontopathic bacteria and antibacterial agents are placed in a periodontal pocket with the intention of enhancing the local effect. To maximize the therapeutic effects while reducing the adverse effects, tinidazole was delivered by in situ forming system. One approach for reducing burst release rate was to testify in situ forming effect. The effect of 0%-10% (w/w) polyethylene glycol 400 and 3% (w/w) glycerol on the tinidazole release from a poly(DL-lactide) (PLA) injectable implant was evaluated. The results showed that the in vitro initial burst release rate was decreased in the presence of poly(ethyleneglycol) PEG 400 and glycerol. A formulation containing 30% (w/w) PLA (M(w) 7300) dissolved in 62% (w/w) N-methyl-2-pyrrolidone, 5% (w/w) PEG 400, and 3%(w/w) glycerol with 5% (w/w) tinidazole was shown to be optimum. Twelve adult beagle dogs were used in the periodontitis model. The treatment group I, II, and positive control group was administrated with gel containing 5%(w/w) tinidazole, 2.5%(w/w) tinidazole, and periocline, respectively. Dog studies revealed that periocline and the developed formulation could significantly decrease symptoms of periodontitis, and they were better than gel containing 2.5% (w/w) tinidazole. The developed formulation could sustain the release of tinidazole for local delivery over 7 days. These findings suggested that the developed formulation was a viable alternative to conventional drug to cure periodontitis.
Asunto(s)
Antitricomonas/farmacología , Implantes Dentales , Periodontitis/terapia , Poliésteres/farmacología , Tinidazol/farmacología , Animales , Antitricomonas/química , Perros , Humanos , Poliésteres/química , Tinidazol/químicaRESUMEN
Trichomonosis is a common sexually transmitted infectious disease linked to reproductive health complications. Recently, the benzimidazole nucleus has emerged as a promising scaffold to develop new trichomonicidal agents. Despite the fact that large amounts of experimental data have been accumulated over the past eight years, no quantitative studies have yet been reported on this class of compounds. In our effort to develop new antiparasitic benzimidazole derivatives, we report in this paper CoMFA and CoMSIA studies with an initial set of 70 benzimidazole derivatives with trichomonicidal activity. Four CoMFA models and eight CoMSIA models were generated; ten of these models had values of r(2) > 0.6 and q(2) > 0.5. The best CoMFA model had r(2) = 0.936 and q(2) = 0.634, and the best CoMSIA model had r(2) = 0.858 and q(2) = 0.642. These models were generated by using two conformer selection methodologies (minimum energy conformations and 3D similarity), and three charge types (Mulliken, Gasteiger-Hükel and electrostatic potential atomic charges). The putative active tautomers of 1H-benzimidazole derivatives were selected using 3D-QSAR calculations. All models were validated via an external test set with 13 molecules. The best models satisfied additional validation criteria. The contour maps generated show the most important features that a benzimidazole derivative should have for trichomonicidal activity; they also, suggest that substituents at the 2- and 6-positions are important in the generation of derivatives with strong activity.
Asunto(s)
Antitricomonas/química , Bencimidazoles/química , Diseño de Fármacos , Trichomonas vaginalis/efectos de los fármacos , Algoritmos , Antitricomonas/farmacología , Bencimidazoles/farmacología , Sitios de Unión , Electrones , Humanos , Cómputos Matemáticos , Modelos Moleculares , Conformación Molecular , Relación Estructura-Actividad Cuantitativa , Estereoisomerismo , Termodinámica , Tricomoniasis/tratamiento farmacológico , Tricomoniasis/parasitología , Trichomonas vaginalis/crecimiento & desarrolloRESUMEN
The Amaryllidaceae family is known by its ornamental and medicinal value and has attracted considerable attention due to the content of alkaloids of its species, which showed interesting biological properties. The present study evaluated the anti-Trichomonas vaginalis activity of eighteen extracts (12.5 to 0.19 mg/mL) and six isolated alkaloids (125 to 1.9 µg/mL) from Amaryllidaceae species. The alkaloids diminished the trophozoites viability (from 15 to 40 %). The extracts from Hippeastrum breviflorum demonstrated the highest anti-T. vaginalis activity (viability was 60 % reduced), and a bioguided study was conducted. Six fractions with antiprotozoal activity had lycorine and lycosinine as major components suggesting a synergistic effect, taking into account the higher anti-T. vaginalis activity of extracts when compared to isolated alkaloids. Our results point out the antiprotozoal potential of the Amaryllidaceae species against T. vaginalis. This parasite causes trichomonosis, the most prevalent nonviral sexually transmitted diseases (STD) worldwide and a public health problem that requires new therapeutic alternatives as well bioactive natural products.
Asunto(s)
Antitricomonas/química , Antitricomonas/farmacología , Liliaceae/química , Trichomonas vaginalis/efectos de los fármacos , 5'-Nucleotidasa/antagonistas & inhibidores , Adenosina/metabolismo , Alcaloides/farmacología , Alcaloides de Amaryllidaceae/química , Alcaloides de Amaryllidaceae/farmacología , Fraccionamiento Químico , Evaluación Preclínica de Medicamentos , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Nucleósido-Trifosfatasa/antagonistas & inhibidores , Fenantridinas/farmacología , Extractos Vegetales/química , Extractos Vegetales/farmacología , Raíces de Plantas/química , Trofozoítos/efectos de los fármacosRESUMEN
Trichomoniasis vaginalis is now an important worldwide health problem. Metronidazole has so far been used in treatment, but the metronidazole-resistant strains and unpleasant adverse effects have been developed. Treatment of patients with metronidazole refractory vaginal trichomoniasis constitutes a major therapeutic challenge and treatment options are extremely limited. In the present study, 33 metronidazole-resistant T. vaginalis females were treated with a combined course of metronidazole and tinidazole. Those still resistant to the combined treatment were given Commiphora molmol (Myrrh) as two capsules for six to eight successive days on an empty stomach two hours before breakfast. Also, natural plant extract purified from (Roman) was in-vitro investigated for its efficacy against T. vaginalis on fresh Diamond media. The anti-trichomoniasis vaginalis activity of both P. granatum (in-vitro) and C. molmol (in-vivo) extracts gave promising results.
Asunto(s)
Commiphora/química , Lythraceae/química , Extractos Vegetales/uso terapéutico , Vaginitis por Trichomonas/tratamiento farmacológico , Animales , Antitricomonas/química , Antitricomonas/uso terapéutico , Relación Dosis-Respuesta a Droga , Resistencia a Medicamentos , Femenino , Humanos , Metronidazol/farmacología , Extractos Vegetales/química , Tinidazol/farmacología , Trichomonas vaginalis/efectos de los fármacosRESUMEN
Bond-based quadratic indices, new TOMOCOMD-CARDD molecular descriptors, and linear discriminant analysis (LDA) were used to discover novel lead trichomonacidals. The obtained LDA-based quantitative structure-activity relationships (QSAR) models, using nonstochastic and stochastic indices, were able to classify correctly 87.91% (87.50%) and 89.01% (84.38%) of the chemicals in training (test) sets, respectively. They showed large Matthews correlation coefficients of 0.75 (0.71) and 0.78 (0.65) for the training (test) sets, correspondingly. Later, both models were applied to the virtual screening of 21 chemicals to find new lead antitrichomonal agents. Predictions agreed with experimental results to a great extent because a correct classification for both models of 95.24% (20 of 21) of the chemicals was obtained. Of the 21 compounds that were screened and synthesized, 2 molecules (chemicals G-1, UC-245) showed high to moderate cytocidal activity at the concentration of 10 microg/ml, another 2 compounds (G-0 and CRIS-148) showed high cytocidal activity only at the concentration of 100 microg/ml, and the remaining chemicals (from CRIS-105 to CRIS-153, except CRIS-148) were inactive at these assayed concentrations. Finally, the best candidate, G-1 (cytocidal activity of 100% at 10 microg/ml) was in vivo assayed in ovariectomized Wistar rats achieving promising results as a trichomonacidal drug-like compound.
Asunto(s)
Antitricomonas/química , Antitricomonas/farmacología , Diseño Asistido por Computadora , Evaluación Preclínica de Medicamentos/métodos , Programas Informáticos , Trichomonas vaginalis/efectos de los fármacos , Adulto , Animales , Antitricomonas/uso terapéutico , Análisis Discriminante , Farmacorresistencia Bacteriana , Femenino , Humanos , Estructura Molecular , Ovariectomía , Ratas , Ratas Wistar , Tricomoniasis/tratamiento farmacológicoRESUMEN
Trichomoniasis is now an important health problem in developing countries. Although metronidazole has so far been widely used to treat this disease, the prevalence of metronidazole-resistant protozoa and unpleasant adverse effects have been found. In this study, natural products purified from Thai plants were, therefore, investigated for their effectiveness against Trichomonas vaginalis. The minimal inhibitory concentrations for all beta-glycosides against Trichomonas vaginalis at 24 h were in a range of 6.25-12.5 microM. In addition, torvoside A and H were found to be more potent than their corresponding aglycones, deglucosylated torvoside A and H, while other beta-glycosides were generally as active as their corresponding aglycones. The cytotoxicity of these compounds was also determined. Except for dalcochinin, none of the tested compounds showed cytotoxicity against Vero and cancer cell lines (KB and MCF-7), having IC(50) values greater than 50 microg/ml. In conclusion, beta-glycosides and several aglycones showed selective inhibition against Trichomonas vaginalis without harmful effect to mammalian cells.
Asunto(s)
Antitricomonas/farmacología , Glicósidos/farmacología , Plantas Medicinales/química , Trichomonas vaginalis/efectos de los fármacos , Animales , Antitricomonas/química , Antitricomonas/toxicidad , Línea Celular Tumoral/efectos de los fármacos , Chlorocebus aethiops , Glicósidos/química , Glicósidos/toxicidad , Humanos , Concentración 50 Inhibidora , Pruebas de Sensibilidad Parasitaria , Tailandia , Células Vero/efectos de los fármacosRESUMEN
Trichomonas vaginalis (Tv) is the causative agent of the most common, non-viral, sexually transmitted disease in women and men worldwide. Since 1959, metronidazole (MTZ) has been the drug of choice in the systemic treatment of trichomoniasis. However, resistance to MTZ in some patients and the great cost associated with the development of new trichomonacidals make necessary the development of computational methods that shorten the drug discovery pipeline. Toward this end, bond-based linear indices, new TOMOCOMD-CARDD molecular descriptors, and linear discriminant analysis were used to discover novel trichomonacidal chemicals. The obtained models, using non-stochastic and stochastic indices, are able to classify correctly 89.01% (87.50%) and 82.42% (84.38%) of the chemicals in the training (test) sets, respectively. These results validate the models for their use in the ligand-based virtual screening. In addition, they show large Matthews' correlation coefficients (C) of 0.78 (0.71) and 0.65 (0.65) for the training (test) sets, correspondingly. The result of predictions on the 10% full-out cross-validation test also evidences the robustness of the obtained models. Later, both models are applied to the virtual screening of 12 compounds already proved against Tv. As a result, they correctly classify 10 out of 12 (83.33%) and 9 out of 12 (75.00%) of the chemicals, respectively; which is the most important criterion for validating the models. Besides, these classification functions are applied to a library of seven chemicals in order to find novel antitrichomonal agents. These compounds are synthesized and tested for in vitro activity against Tv. As a result, experimental observations approached to theoretical predictions, since it was obtained a correct classification of 85.71% (6 out of 7) of the chemicals. Moreover, out of the seven compounds that are screened, synthesized and biologically assayed, six compounds (VA7-34, VA7-35, VA7-37, VA7-38, VA7-68, VA7-70) show pronounced cytocidal activity at the concentration of 100 mug/ml at 24 h (48 h) within the range of 98.66%-100% (99.40%-100%), while only two molecules (chemicals VA7-37 and VA7-38) show high cytocidal activity at the concentration of 10 mug/ml at 24 h (48 h): 98.38% (94.23%) and 97.59% (98.10%), correspondingly. The LDA-assisted QSAR models presented here could significantly reduce the number of synthesized and tested compounds and could increase the chance of finding new chemical entities with anti-trichomonal activity.